In 1993, enoxaparin, a low-molecular-weight heparin, was approved for medical use. It offered more predictable anticoagulant effects than unfractionated heparin and could often be given by subcutaneous injection. It became widely used for preventing and treating deep vein thrombosis and pulmonary embolism.

The approval of enoxaparin for medical use in 1993 helped streamline clot prevention after surgery and illness. For creative lives, such advancements reduce the risk of temporary interruptions becoming final silences, allowing poets to explore themes of continuity and resilience in their works.